A detailed history of Captrust Financial Advisors transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 16,199 shares of NUVB stock, worth $78,727. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,199
Holding current value
$78,727
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$1.66 - $2.53 $26,890 - $40,983
16,199 New
16,199 $31,000
Q2 2022

Aug 16, 2022

SELL
$3.24 - $5.85 $145 - $263
-45 Reduced 14.61%
263 $1,000
Q1 2022

May 16, 2022

BUY
$4.6 - $8.83 $1,416 - $2,719
308 New
308 $2,000
Q3 2021

Nov 16, 2021

SELL
$7.78 - $10.0 $210 - $270
-27 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $248 - $390
27 New
27 $0

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $1.06B
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.